107.521 articles found

Accurate differentiation of parkinsonism and essential tremor using visual assessment of [¹²³ I]-FP-CIT SPECT imaging: The [¹²³ I]-FP-CIT study group.

Benamer HTS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, Speelman JD, Horstink MHIM, Sips HJWA, Dierckx RA, Versijpt J, Decoo D, Van Der Linden C, Hadley DM, Doder M, Lees AJ, Costa DC, Gacinovic S, Oertel WH, Pogarell O, Hoeffken H, Joseph K, Tatsch K, Schwarz J, Ries V.

Mov Disord · 2000-05-01

DOI: 10.1002/1531-8257(200005)15:3<503::aid-mds1013>3.0.co;2-vPMID: 28470733

Gender differences in the frequency and treatment of behavior problems in Parkinson's disease.

Fernandez HH, Lapane KL, Ott BR, Friedman JH.

Mov Disord · 2000-05-01

DOI: 10.1002/1531-8257(200005)15:3<490::aid-mds1011>3.0.co;2-ePMID: 28470738

Methods for treating Parkinson's disease using optically pure (-)-bupropion

YOUNG JAMES W.

· 2000-04-20

Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases.

Alexi T, Borlongan CV, Faull RL, Williams CE, Clark RG, Gluckman PD, Hughes PE.

Prog Neurobiol · 2000-04-01

DOI: 10.1016/s0301-0082(99)00032-5PMID: 10697073

Calpastatin immunoreactivity in the monkey and human brain of control subjects and patients with Parkinson's disease.

Mouatt-Prigent A, Karlsson JO, Yelnik J, Agid Y, Hirsch EC.

J Comp Neurol · 2000-04-01

DOI: 10.1002/(sici)1096-9861(20000403)419:2<175::aid-cne3>3.0.co;2-2PMID: 10722997

Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies.

Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ.

J Neurol Neurosurg Psychiatry · 2000-04-01

DOI: 10.1136/jnnp.68.4.423PMID: 10727476

Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score.

Araki I, Kuno S.

J Neurol Neurosurg Psychiatry · 2000-04-01

DOI: 10.1136/jnnp.68.4.429PMID: 10727477

What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease?

Wenning GK, Ben-Shlomo Y, Hughes A, Daniel SE, Lees A, Quinn NP.

J Neurol Neurosurg Psychiatry · 2000-04-01

DOI: 10.1136/jnnp.68.4.434PMID: 10727478

The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation.

Boireau A, Dubedat P, Bordier F, Imperato A, Moussaoui S.

Neuropharmacology · 2000-04-01

DOI: 10.1016/s0028-3908(99)00188-4PMID: 10727711

Interaction among mitochondria, mitogen-activated protein kinases, and nuclear factor-kappaB in cellular models of Parkinson's disease.

Cassarino DS, Halvorsen EM, Swerdlow RH, Abramova NN, Parker WD, Sturgill TW, Bennett JP.

J Neurochem · 2000-04-01

DOI: 10.1046/j.1471-4159.2000.0741384.xPMID: 10737593

Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease.

Soto-Otero R, Méndez-Alvarez E, Hermida-Ameijeiras A, Muñoz-Patiño AM, Labandeira-Garcia JL.

J Neurochem · 2000-04-01

DOI: 10.1046/j.1471-4159.2000.0741605.xPMID: 10737618

Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.

Fénelon G, Mahieux F, Huon R, Ziégler M.

Brain · 2000-04-01

DOI: 10.1093/brain/123.4.733PMID: 10734005